Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ten year trend keeping its direction!
They do not make money.
Ceo promisses progress, none comes and they dilute with continued equity raises.
Sadly they have a bad reputation for being vague, not delivering and diluting.
A good stock to play on news releases but not one to hold.
Thw volume explains all. Intense on article, now everyone loosing interest
I always think one of the OEMs could create a strategic market advantage by acquiring Kromek - maybe the spread of shareholders makes this difficult and also hard to build
up any sizeable holding on the open market. Certainly if I owned a sizeable OEM this would be high up on my list to assess. iMHO DYOR GLA
Looking back over old articles and broker reports on the number of OEMs that KROMEK have said they’ve been engaged with,
It’s been steadily rising from 11 OEMs in July 2018 (IC article) to 15? odd now as mentioned by Finncap recently.
Along with the CZT furnace capacity increasing by 5 fold UK & US Pittsburgh? to x154 using funds from the last fund raise, they are well
placed to ramp up production for these new contracts and delivery agreements just announced, and any news ones to come.
the other OEMs which are expected to sign formal contracts have been
working with Kromek for a similar considerable number of years as well by the look of it. so likely in advanced prototype testing and validation
phases and planning to launch CZT based scanners in the near future , so more OEM contract news coming soon hopefully.
From the last paragraph of the Finncap report it was stated...
''The validation and endorsement that this agreement (first tier 1 customer signing) brings is expected to drive the remaining OEMs to source CZT from Kromek.
This group of OEMs accounts for est 10-15% of the current market, which represents a current end-user CT CZT market value of the region $0.8-1.0bn.
We expect Kromek to win additional customers looking for CZT detection solutions in both SPECT and CT.
Tier 2 CT OEMs accounted for an estimated 12% share of the CT market in 2022''
So who's left -
Philips Medical Systems (last tier 1) - been mentioned many times but yet to sign on the dotted line
So the remaining tier 2 CT CZT medical imaging companies that Kromek are engaged with are -
UNITED IMAGING - regularly mentioned
NEUROLOGICA - subsidiary of Samsung
FUJI - Medical Systems
MARS Bio-imaging - metabolic and functional imaging for drug development studies
Mediso - of Budapest
Toshiba - Japan
Hitachi - were engaged with Redlen (Canon now) - 2016?
GMI+ can't find anything on them..
++++ a couple of others unknowns by the sound of it.
Every OEM Medical Imaging contract bagged will very likely be a long production runs, with good earnings visibility.
I can’t see the share price staying at this level for long when the penny drops.
So that is it. Wonderful news from this impressive outfit. The sp struggles to cling on around 8p.. Seems there are only a few mugs buying into this great story. The majority read the same old promises, promises tag line.
Thanks Mike - the fact that Kromek have been delivering against this contract on a continuous basis must have given others confidence and is a significant recurring revenue stream. Obviously wouldn’t expect Kromek to issue details of whether they are exceeded or not the original forecast volumes…. IMHO DYOR GLA
Hmmm?
given that Kromek signed a $58.1m 7-year supply agreement in 2019 with a Tier 2 OEM now just announced as Spectrum Dynamics,
(i previously thought it was with Philips)
It’s probably safe to say that the Bath's RUH Hospital's recent purchase of a new Spectrum Dynamics VERITON CT scanner uses Kromeks CZT modules.
this being the first of its kind to be installed anywhere in the UK.
https://spectrum-dynamics.com/royal-united-hospitals-bath-nhs-foundation-trust-united-kingdom/
Hmmm?
Impressive company -
https://www.analogic.com/wp-content/uploads/2021/05/Analogic-Compressed-1.mp4
We were at 11/12p a few months ago before recent game changing news. Will be short term traders and maybe some volatility but suspect market has been given major assurance now from Kromek actions…Only £36m market cap !!!! IMHO DYOR GLA
Slow rise to 30p will do me......This company has the technology.....just need to get it out there.....Next 18 months will be interesting.....
It is fair to say that based on this volume we are heading out of the single digit share price territory. 30m shares traded in the last 3 days plus more today. We went down so quickly in the last month a rise back to 10p seems reasonable in the next few trading days if the volume continues. Let's hope for some weekend press coverage.
I haven’t seen any timescales from brokers/analysts which is the norm… they value based on discounted cash flow only…. Nice to see a turn in sentiment at long last backed by the announcements and analysts views. IMHO DYOR GLA
As b00mb0y replied over on ADVFN.
So then. .32 coming? How long till this price is reached? 300% from here.
Just received Investors Chronicle Ideas of the Week email. Highlights that Analysts think share price will quadruple from current levels. GLA
Look at who owns Kromek:
https://www.kromek.com/investor-relations/shareholder-information/significant-shareholders/
I knew the management owned a tiny percentage but I was surprised to see former Kromek directors own more than CURRENT directors. I’d refer you to skid35 for details on that.
Good post. If I were Siemens or Philips, I'd be buying a good chunk of KMK either now or at some point soon.
kromeks -tier 1 customer -
its either Siemens or Philips, each a world leading medical imaging company and a fantastic endorsement for KMKs engineering.
The CT global market was worth est. -$6.7bn in 2022 and is forecast to grow to Approx.. $10bn by 2030. Assuming CZT modules represent approx.. 20% by value of a CZT-based CT scanner,
it implies a potential es.t -$2bn CZT market in 2030. We estimate the four existing Tier 1 OEMs in the CT imaging market to
share approx.. 85-90% of this market. (Based on the CZT component modules being approx.. 15-20% CT market share), it would imply an
es.t-$300-400m potential addressable market from this 'just announced' KMK Tier 1 OEM contract alone.
It’s believed that this Tier 1 OEM will have entered this long-term agreement satisfied that Kromek’s technical capabilities,
quality systems and IP are robust and that its production facilities are capable of scaling to meet the customer’s expected demand.
After long periods of scoping and spec engineering team work.
Siemens whilst not named for commercial reasons could be the tier 1 customer, given that its (own in house) cadmium-telluride detectors are not deemed to be suitable for SPECT imaging.
In 2010, Siemens acquired Acorad (Japan) to enable it to develop a cadmium telluride-based CT system.
In 2021, Siemens launched the world's first photon-counting computed tomography (PCCT) scanner,
Naeotom Alpha, illustrating the time and investment commitment by a global imaging company to develop this market.
The other only remaining Tier 1 OEM is Philips Medical Systems, which would be expected to participate in this transition, or run the risk of losing its market share to the next-generation of advanced CT scanners.
Philips has no known in-house CZT manufacturing capabilities.
Canon and GE both have acquired their own CZT manufactures, at considerable cost.
We have had a number of cash raises over the years, almost doubling the shares in the market since float (2013). With cash burn now under some control and the investments in the products made, it is time to earn some money for shareholders, not dilute them further. Confidence will be a big thing here, most existing shareholders have little but I hope the tide is turning, the volume in the last few days speaks for itself, and we'll have some shareholders already in profit. It'll be a while for me.
great news this week, anyone think they may fundraise anytime soon?.
i quite like the look of this.
The significance of these milestone contract wins is only just starting to be fully appreciated by the market.
The IC article is bound to attract a number of new investors over the coming days and articulates the potential upside very well.
For the first time in many months I am once again feeling sanguine about KMK's prospects.
A slow rise to 30p over a year to 18 months will be rewarding to those who believe this company has a great future........
and interview
..........
https://www.proactiveinvestors.co.uk/companies/news/1012757/kromek-group-announces-two-key-contract-wins-1012757.html
............
Well,,Acq888 and skid35 you have "nailed it "... Empty promises and lack of any investment from Basu over many years explains why the recent Wonderful news has seen the sp barely move..Long term investors think in terms of snake oil salesmen. A share price close to 10p requires many new investors ignorant of the history of Kromek. To invest now is to believe something has changed in Durham..My thoughts are on the lines of "doing the same thing over and over again and expecting a different result !"